Vertex Pharmaceuticals Inc VRTX

NASDAQ US Health Care Biotechnology

$526.19 ▲ +0.73% (+$3.81)

Index member: S&P 500

Open $522.55

Prev Close $522.38

Day Range $518.92 – $527.69

52W Range $374.17 – $560.25

Market Cap $121.09B

P/E (TTM) 30.46

Beta 0.28

EPS (TTM) $17.19

📋 Company Profile

Industry	Biotechnology
Sector	Health Care
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1991-07-24
Shares Out.	253,810,000
Website	vrtx.com/ ↗
Phone	16173416393
Employees	6,400
Revenue	$3.33B
Gross Profit	$2.84B
Net Income	$1.10B
Free Cash Flow	$3.80B
Total Assets	$27.42B
Total Liabilities	$7.18B
Equity	$20.25B

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals Inc is a publicly traded company under the ticker symbol VRTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.